Teva Pharmaceutical Industries (TEVA) Research & Development (2017 - 2026)

Teva Pharmaceutical Industries' Research & Development history runs 10 years deep, the most recent figure standing at $696.0 million for Q1 2026.

• Quarterly Research & Development rose 181.78% year-over-year to $696.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.5 billion (up 2688.32% YoY) and the FY2025 annual result came in at $2.7 billion, up 169.14% from the prior year.
• Research & Development was $696.0 million for Q1 2026 at Teva Pharmaceutical Industries, down from $1.9 billion in the prior quarter.
• Across five years, Research & Development topped out at $1.9 billion in Q4 2025 and bottomed at -$893.0 million in Q4 2024.
• A 5-year average of $522.8 million and a median of $549.0 million in 2022 frame the typical range for Research & Development.
• Annual changes were most pronounced in 2024 — Research & Development tumbled 155.47% — and 2025, when it surged 317.25%.
• Teva Pharmaceutical Industries' Research & Development stood at $549.0 million in 2022, then surged by 193.26% to $1.6 billion in 2023, then plunged by 155.47% to -$893.0 million in 2024, then jumped by 317.25% to $1.9 billion in 2025, then sank by 64.12% to $696.0 million in 2026.
• Business Quant data shows TEVA's Research & Development at $696.0 million in Q1 2026, $1.9 billion in Q4 2025, and $256.0 million in Q3 2025.